Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Carbios a fortement réduit ses charges opérationnelles au cours de l’année 2025, permettant une réduction de la perte d’exploitation de 7 millions d’eurosCarbios dispose d’une trésorerie solide à...
-
Carbios significantly reduced its operating expenses during 2025, resulting in a €7 million reduction in operating lossCarbios has a solid cash position of €59 million as of December 31, 2025, on a...
-
Gereglementeerde Informatie Nyrstar NV Jaarresultaten 2025 17 april 2026 om 07.00 CEST Nyrstar NV ("Nyrstar" of de “Vennootschap”) kondigt vandaag de publicatie van haar jaarrekening aan voor de...
-
Regulated Information Nyrstar NV 2025 Full Year Results 17 April 2025 at 07:00 CEST Nyrstar NV ("Nyrstar" or the “Company”) is today announcing the publication of its financial statements for the...
-
The shares in Borregaard ASA will be traded ex-dividend of NOK 4.75 per share as from today, 17 April 2026. Borregaard ASASarpsborg, 17 April 2026 Contact:Lotte Kvinlaug, Investor Relations Officer,...
-
Colorado Springs, CO, April 16, 2026 (GLOBE NEWSWIRE) -- Elevate Trampoline Park is opening a new 31,000-square-foot indoor activity center in Colorado Springs, creating a new destination for...
-
Male Excel TRT 2026: Claims Examined, Pricing Verified & What Consumers Should Confirm Before Buying
New York City, NY, April 16, 2026 (GLOBE NEWSWIRE) -- It starts so gradually you almost miss it. The alarm goes off, and instead of jumping out of bed, you lie there a few minutes longer, not...
-
New York City, NY, April 16, 2026 (GLOBE NEWSWIRE) -- Many U.S. online casinos promote attractive rewards, but players often face hidden conditions, slow payouts, and unclear rules when trying to...
-
COMMUNIQUÉ DE PRESSE AB SCIENCE FAIT LE POINT SUR SON PROGRAMME CLINIQUE AB SCIENCE OBTIENT UNE ASSURANCE D'ESSAIS CLINIQUES DE 25 MILLIONS D'EUROS POUR SON ETUDE DE PHASE III SUR LA SCLÉROSE...
-
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON ITS CLINICAL PROGRAM AB SCIENCE SECURES EUR 25 MILLION CLINICAL TRIAL INSURANCE FOR ITS PHASE III TRIAL IN AMYOTROPHIC LATERAL SCLEROSIS THE POLICY...